Celino

Celino is a biotechnology company developing an automated, AI-guided platform for the high-throughput manufacturing of autologous induced pluripotent stem cell (iPSC) therapies. By combining laser-based cell processing with machine learning and robotics, the company aims to eliminate the need for manual intervention in cell culture, significantly reducing costs and increasing the scalability of personalized regenerative medicines. Their technology focuses on identifying and removing unwanted cells with high precision to ensure the safety and efficacy of the final therapeutic product. Celino's initial pipeline targets high-prevalence conditions such as Parkinson's disease and age-related macular degeneration. The company's mission is to make personalized cell therapies accessible to patients at scale through advanced automation.